Literature DB >> 22906296

The Shigella human challenge model.

C K Porter1, N Thura1, R T Ranallo2, M S Riddle1.   

Abstract

Shigella is an important bacterial cause of infectious diarrhoea globally. The Shigella human challenge model has been used since 1946 for a variety of objectives including understanding disease pathogenesis, human immune responses and allowing for an early assessment of vaccine efficacy. A systematic review of the literature regarding experimental shigellosis in human subjects was conducted. Summative estimates were calculated by strain and dose. While a total of 19 studies evaluating nine strains at doses ranging from 10 to 1 × 1010 colony-forming units were identified, most studies utilized the S. sonnei strain 53G and the S. flexneri strain 2457T. Inoculum solution and pre-inoculation buffering has varied over time although diarrhoea attack rates do not appear to increase above 75-80%, and dysentery rates remain fairly constant, highlighting the need for additional dose-ranging studies. Expansion of the model to include additional strains from different serotypes will elucidate serotype and strain-specific outcome variability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906296      PMCID: PMC9152033          DOI: 10.1017/S0950268812001677

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  31 in total

1.  The ethical challenge of infection-inducing challenge experiments.

Authors:  F G Miller; C Grady
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 3.  Post-infectious irritable bowel syndrome--a review of the literature.

Authors:  J Schwille-Kiuntke; J-S Frick; P Zanger; P Enck
Journal:  Z Gastroenterol       Date:  2011-08-02       Impact factor: 2.000

4.  Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.

Authors:  L L Van De Verg; N O Bendiuk; K Kotloff; M M Marsh; J L Ruckert; J L Puryear; D N Taylor; A B Hartman
Journal:  Vaccine       Date:  1996-08       Impact factor: 3.641

5.  The response of man to virulent Shigella flexneri 2a.

Authors:  H L DuPont; R B Hornick; A T Dawkins; M J Snyder; S B Formal
Journal:  J Infect Dis       Date:  1969-03       Impact factor: 5.226

6.  Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.

Authors:  D A Herrington; L Van de Verg; S B Formal; T L Hale; B D Tall; S J Cryz; E C Tramont; M M Levine
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

7.  Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Authors:  T S Coster; C W Hoge; L L VanDeVerg; A B Hartman; E V Oaks; M M Venkatesan; D Cohen; G Robin; A Fontaine-Thompson; P J Sansonetti; T L Hale
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis.

Authors:  P A Mackowiak; S S Wasserman; M M Levine
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

9.  Challenge studies of human volunteers: ethical issues.

Authors:  T Hope; J McMillan
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

10.  Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.

Authors:  R E Black; M M Levine; M L Clements; G Losonsky; D Herrington; S Berman; S B Formal
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

View more
  12 in total

Review 1.  Salmonella, Shigella, and yersinia.

Authors:  John P Dekker; Karen M Frank
Journal:  Clin Lab Med       Date:  2015-04-02       Impact factor: 1.935

Review 2.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

Review 3.  Zika Vaccines: Role for Controlled Human Infection.

Authors:  Anna P Durbin; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2017-12-16       Impact factor: 5.226

Review 4.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

5.  A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.

Authors:  Courtney L Davis; Rezwanul Wahid; Franklin R Toapanta; Jakub K Simon; Marcelo B Sztein
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

6.  Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Authors:  Chad K Porter; Amanda Lynen; Mark S Riddle; Kawsar Talaat; David Sack; Ramiro L Gutiérrez; Robin McKenzie; Barbara DeNearing; Brittany Feijoo; Robert W Kaminski; David N Taylor; Beth D Kirkpatrick; A Louis Bourgeois
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

7.  Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.

Authors:  Kawsar R Talaat; A Louis Bourgeois; Robert W Frenck; Wilbur H Chen; Calman A MacLennan; Mark S Riddle; Akamol E Suvarnapunya; Jessica L Brubaker; Karen L Kotloff; Chad K Porter
Journal:  Clin Infect Dis       Date:  2019-12-09       Impact factor: 9.079

8.  Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview.

Authors:  Calman A MacLennan; Anastazia Older Aguilar; A Duncan Steele
Journal:  Clin Infect Dis       Date:  2019-12-09       Impact factor: 9.079

9.  An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

Authors:  Chad K Porter; Mark S Riddle; Ashley N Alcala; David A Sack; Clayton Harro; Subhra Chakraborty; Ramiro L Gutierrez; Stephen J Savarino; Michael Darsley; Robin McKenzie; Barbara DeNearing; Hans Steinsland; David R Tribble; A Louis Bourgeois
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

10.  An Oral Inoculation Infant Rabbit Model for Shigella Infection.

Authors:  Carole J Kuehl; Jonathan D D'Gama; Alyson R Warr; Matthew K Waldor
Journal:  mBio       Date:  2020-01-21       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.